KIN1400

KIN1400 is a potent IRF3 activator. KIN1400 triggers IRF3-dependent innate immune antiviral genes (RIG-I, MDA5, IFIT1, and Mx1) and IFN-β expression. KIN1400 inhibits WNV and DV, two mosquito-borne members of the Flaviviridae and the genus Flavivirus. KIN1400 also inhibits HCV replication. KIN1400 induces innate antiviral immunity through a MAVS-IRF3 axis[1].

Product Specifications

CAS Number

[446826-86-4]

UNSPSC

12352005

Target

HCV; IFNAR

Type

Reference compound

Related Pathways

Anti-infection; Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/kin1400.html

Purity

98.1

Solubility

DMSO : 30 mg/mL (ultrasonic; warming)

Smiles

OC1=C2N=CC=CC2=CC=C1C(NC3=NC4=CC=CC=C4S3)C5=CC=C(OC(F)F)C=C5

Molecular Formula

C24H17F2N3O2S

Molecular Weight

449.47

References & Citations

[1]Pattabhi S, et al. Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway. J Virol. 2015 Dec 16;90 (5) :2372-87.